DE60026557T2 - Cephalotaxine, ihre herstellung und ihre verwendung in der behandlung von krebs, leukämie, parasiten einschliesslich derjenigen die gegen übliche chemotherapeutika resistent sind und als umkehrende mittel - Google Patents

Cephalotaxine, ihre herstellung und ihre verwendung in der behandlung von krebs, leukämie, parasiten einschliesslich derjenigen die gegen übliche chemotherapeutika resistent sind und als umkehrende mittel Download PDF

Info

Publication number
DE60026557T2
DE60026557T2 DE60026557T DE60026557T DE60026557T2 DE 60026557 T2 DE60026557 T2 DE 60026557T2 DE 60026557 T DE60026557 T DE 60026557T DE 60026557 T DE60026557 T DE 60026557T DE 60026557 T2 DE60026557 T2 DE 60026557T2
Authority
DE
Germany
Prior art keywords
dichloromethane
mmol
och
alkyl
resulting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60026557T
Other languages
German (de)
English (en)
Other versions
DE60026557D1 (de
Inventor
Jean-Pierre Robin
Robert Dhal
Freddy Drouye
Jean-Pierre Marie
Nina Radosevic
Julie Robin
Karine Souchaud
Patricia Bataille
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ChemGenex Pharmaceuticals Pty Ltd
Original Assignee
Stragen Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stragen Pharma SA filed Critical Stragen Pharma SA
Application granted granted Critical
Publication of DE60026557D1 publication Critical patent/DE60026557D1/de
Publication of DE60026557T2 publication Critical patent/DE60026557T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE60026557T 2000-10-17 2000-10-17 Cephalotaxine, ihre herstellung und ihre verwendung in der behandlung von krebs, leukämie, parasiten einschliesslich derjenigen die gegen übliche chemotherapeutika resistent sind und als umkehrende mittel Expired - Lifetime DE60026557T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2000/001593 WO2002032904A1 (en) 2000-10-17 2000-10-17 New cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including thus resistant to usual chemotherapeutic agents and as reversal agents

Publications (2)

Publication Number Publication Date
DE60026557D1 DE60026557D1 (de) 2006-05-04
DE60026557T2 true DE60026557T2 (de) 2006-12-28

Family

ID=11003995

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60026557T Expired - Lifetime DE60026557T2 (de) 2000-10-17 2000-10-17 Cephalotaxine, ihre herstellung und ihre verwendung in der behandlung von krebs, leukämie, parasiten einschliesslich derjenigen die gegen übliche chemotherapeutika resistent sind und als umkehrende mittel

Country Status (12)

Country Link
US (1) US6579869B1 (enExample)
EP (1) EP1328527B1 (enExample)
JP (1) JP4837233B2 (enExample)
CN (1) CN1303084C (enExample)
AT (1) ATE319714T1 (enExample)
AU (1) AU7940500A (enExample)
CA (1) CA2426103A1 (enExample)
DE (1) DE60026557T2 (enExample)
DK (1) DK1328527T3 (enExample)
ES (1) ES2258024T3 (enExample)
PT (1) PT1328527E (enExample)
WO (1) WO2002032904A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285546B2 (en) * 2000-10-17 2007-10-23 Stragen Pharma S.A. Cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including those resistant to usual chemotherapeutic agents and as reversal agents
US20020128258A1 (en) * 2001-03-09 2002-09-12 Jean-Pierre Robin Therapeutical method involving subcutaneous administration of drugs containing cephalotaxine derivatives
WO2004009092A1 (en) 2002-07-17 2004-01-29 Chemgenex Pharmaceuticals Limited Formulations and methods of administration of cephalotaxines, including homoharringtonine
US7642252B2 (en) 2002-07-22 2010-01-05 Chemgenex Pharmaceuticals, Inc. Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
WO2009148654A2 (en) 2008-03-03 2009-12-10 Sloan-Kettering Institute For Cancer Research Cephalotaxus esters, methods of synthesis, and uses thereof
US20120022250A1 (en) * 2009-03-11 2012-01-26 Jean-Pierre Robin Process for preparing cephalotaxine esters
CN102304132B (zh) * 2011-07-12 2015-01-28 南开大学 高效高立体选择性半合成三尖杉酯类生物碱的方法
JP6068472B2 (ja) * 2011-08-18 2017-01-25 ハンジョウ ベンシェン ファーマシューティカル シーオー．， エルティーディー．Ｈａｎｇｚｈｏｕ Ｂｅｎｓｈｅｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． アミノ化ホモハリントニン誘導体、その調製方法及び使用
CN103687859B (zh) * 2011-08-18 2016-08-17 杭州本生药业有限公司 高三尖杉酯碱的胺化衍生物、及其制备方法和应用
CN102675327B (zh) * 2012-03-01 2014-12-10 南开大学 三尖杉酯碱类似物及制备方法和应用
CN104293855A (zh) * 2014-10-15 2015-01-21 中国计量学院 脐孢木霉菌转化株在提高木霉素产量中的应用
WO2016182850A1 (en) 2015-05-08 2016-11-17 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
CN106866690B (zh) * 2015-12-10 2019-10-11 南开大学 三尖杉酯类生物碱、其制备方法和用途
CN109111459B (zh) * 2017-06-22 2021-10-29 南华大学 含水杨酸三尖杉碱酯衍生物、制造方法及其用途
CN108378049A (zh) * 2018-05-02 2018-08-10 孙利嫚 一种含有粗榧生物碱和甲氧虫酰肼的农药组合物
CN119968374A (zh) * 2022-09-22 2025-05-09 南开大学 三尖杉酯碱类衍生物及其药物组合物、制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2776292B1 (fr) * 1998-03-20 2004-09-10 Oncopharm Cephalotaxanes porteurs de chaine laterale et leur procede de synthese

Also Published As

Publication number Publication date
PT1328527E (pt) 2006-06-30
HK1063183A1 (en) 2004-12-17
DK1328527T3 (da) 2006-07-17
CN1303084C (zh) 2007-03-07
CA2426103A1 (en) 2002-04-25
ES2258024T3 (es) 2006-08-16
CN1474821A (zh) 2004-02-11
AU7940500A (en) 2002-04-29
US6579869B1 (en) 2003-06-17
JP2004511560A (ja) 2004-04-15
DE60026557D1 (de) 2006-05-04
EP1328527A1 (en) 2003-07-23
JP4837233B2 (ja) 2011-12-14
WO2002032904A1 (en) 2002-04-25
ATE319714T1 (de) 2006-03-15
EP1328527B1 (en) 2006-03-08

Similar Documents

Publication Publication Date Title
DE60026557T2 (de) Cephalotaxine, ihre herstellung und ihre verwendung in der behandlung von krebs, leukämie, parasiten einschliesslich derjenigen die gegen übliche chemotherapeutika resistent sind und als umkehrende mittel
DE69529897T2 (de) 42-rapamycin hydroxyester, verfahren zu dessen herstellung und diesen enthaltende pharmazeutische zusammensetzungen
EP0013983B1 (de) Antineoplastische Mittel auf Basis von nicht oder nur geringfügig irritierenden und/oder promovierenden Diterpenalkoholen und Derivaten davon und deren Herstellung
DE69923768T2 (de) Cephalotoxanderivative und verfahren zu ihrer herstellung
DE69302249T2 (de) Prolinderivat von Rapamycin, seine Herstellung und Verwendung
DE69728544T2 (de) Totalsynthese von acylfulvenen mit antitumorwirkung
DE69714220T2 (de) Campotecinderivate und ihre verwendung als antitumormittel
DE19547958B4 (de) Anthracyclin-Derivate
DE60225943T2 (de) Topoisomerase-giftmittel
US20110262561A1 (en) Protoilludance Norsesquiterpenoid Esters and Uses Thereof
DE69530205T2 (de) Heterocyclisch kondensierte morphinoid-derivate
DE60308368T3 (de) Camptothecine mit modifiziertem lactonring
DE69406430T2 (de) Alkaloide von Mappie foetida, deren Anwendung und diese enthaltende Zusammensetzungen
DE2347576C2 (de) Bruceantin und diese Verbindung enthaltende antileukämische Mittel
DE3531197A1 (de) Neue 6-substituierte mitomycin-analoge
DE69819340T2 (de) Optisch reine camptothecinanaloge, optisch reines synthese-zwischenprodukt und verfahren zu ihrer herstellung
DE2632118A1 (de) Apovincaminolester und verfahren zu deren herstellung
DE2733867A1 (de) Halbsynthetische oleandomycin-c tief 8 -derivate
DE69228259T2 (de) Neue alpha-mannosidase-inhibitoren
DE60010891T2 (de) Pyridomorphinanen und ihre verwendung
EP1989208B1 (de) Neue morphinverbindungen für pharmazeutische zusammensetzungen
US8486901B2 (en) Sodium channel blocking compounds tetrodotoxin galactopyranosides
DE69901907T2 (de) Fotocyclisierte rapamycine
US7285546B2 (en) Cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including those resistant to usual chemotherapeutic agents and as reversal agents
DE2410201A1 (de) 6-substituierte 3-carbaethoxyhydrazinopyridazine beziehungsweise ihre salze sowie ihre verwendung und verfahren zur herstellung derselben

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CHEMGENEX PHARMACEUTICALS LTD., GEELONG, VICTO, AU